These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

82 related articles for article (PubMed ID: 9784311)

  • 1. DNA content and S-phase fraction in epithelial ovarian cancer: what information do they really add?
    Braly P
    Gynecol Oncol; 1998 Oct; 71(1):1-2. PubMed ID: 9784311
    [No Abstract]   [Full Text] [Related]  

  • 2. Prognostic significance of DNA content and S-phase fraction in epithelial ovarian carcinomas analyzed by image cytometry.
    Reles AE; Gee C; Schellschmidt I; Schmider A; Unger M; Friedmann W; Lichtenegger W; Press MF
    Gynecol Oncol; 1998 Oct; 71(1):3-13. PubMed ID: 9784312
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Multivariate analysis of the prognostic significance of DNA-ploidy and S-phase fraction in ovarian cancer determined by flow cytometry following detection of cytokeratin-labeled tumor cells.
    Kimmig R; Wimberger P; Hillemanns P; Kapsner T; Caspari C; Hepp H
    Gynecol Oncol; 2002 Jan; 84(1):21-31. PubMed ID: 11748971
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Prognostic value of nuclear DNA quantification and cyclin A expression in epithelial ovarian carcinoma.
    Yoon BS; Kim YT; Kim S; Lee CS; Kim JW; Kim JH; Kim SW; Cho NH
    Eur J Obstet Gynecol Reprod Biol; 2008 Jan; 136(1):110-5. PubMed ID: 17157431
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Familial ovarian cancer.
    Ngan HY; Shepherd JH
    Br J Hosp Med; 1994 Jul 13-Aug 16; 52(2-3):99-102. PubMed ID: 7952791
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Cell proliferation in ovarian carcinoma: superior accuracy of S-phase fraction (SPF) by DNA labeling index versus flow cytometric SPF, lack of independent prognostic power for SPF and DNA ploidy, and limited effect of SPF on tumor growth rate.
    Meyer JS; Gersell DJ; Yim S
    Gynecol Oncol; 2001 Jun; 81(3):466-76. PubMed ID: 11371140
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Prognostic value of DNA flow cytometry in stomach cancer: a 5-year prospective study.
    Lee KH; Lee JS; Lee JH; Kim SW; Suh C; Kim WK; Kim SH; Min YI; Kim BS; Park KC; Lee MS; Sun HS
    Br J Cancer; 1999 Apr; 79(11-12):1727-35. PubMed ID: 10206284
    [TBL] [Abstract][Full Text] [Related]  

  • 8. [Diagnosis and prognosis of ovarian epithelial tumor with morphometry].
    Yin TJ; Gu MJ
    Ai Zheng; 2002 Jul; 21(7):781-4. PubMed ID: 12479107
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Flow cytometry vs. Ki67 labelling index in breast cancer: a prospective evaluation of 181 cases.
    Martínez-Arribas F; Núñez MJ; Piqueras V; Lucas AR; Sánchez J; Tejerina A; Schneider J
    Anticancer Res; 2002; 22(1A):295-8. PubMed ID: 12017306
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Activin is a potent growth suppressor of epithelial ovarian cancer cells.
    Ramachandran A; Marshall ES; Love DR; Baguley BC; Shelling AN
    Cancer Lett; 2009 Nov; 285(2):157-65. PubMed ID: 19493612
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Biomarker discovery in epithelial ovarian cancer by genomic approaches.
    Mok SC; Elias KM; Wong KK; Ho K; Bonome T; Birrer MJ
    Adv Cancer Res; 2007; 96():1-22. PubMed ID: 17161674
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Biomarker conservation in primary and metastatic epithelial ovarian cancer.
    Tewari KS; Kyshtoobayeva AS; Mehta RS; Yu IR; Burger RA; DiSaia PJ; Fruehauf JP
    Gynecol Oncol; 2000 Aug; 78(2):130-6. PubMed ID: 10926791
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Proliferating cell nuclear antigen (PCNA) and Ki-67 in epithelial ovarian tumours: correlation with DNA flow cytometric analysis.
    Karaburun S; Karaveli S; Peştereli HE; Simsek T; Sargin CF
    Adv Clin Path; 2001 Jan; 5(1-2):3-9. PubMed ID: 11753828
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Molecular biology and genetics of epithelial ovarian cancer.
    Baker VV
    Obstet Gynecol Clin North Am; 1994 Mar; 21(1):25-40. PubMed ID: 8015765
    [TBL] [Abstract][Full Text] [Related]  

  • 15. RAD52 Y415X truncation polymorphism and epithelial ovarian cancer risk in Australian women.
    Kelemen L; Spurdle AB; Purdie DM; Gertig D; Chenevix-Trench G
    Cancer Lett; 2005 Feb; 218(2):191-7. PubMed ID: 15670896
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Gene-expression profiling in epithelial ovarian cancer.
    Konstantinopoulos PA; Spentzos D; Cannistra SA
    Nat Clin Pract Oncol; 2008 Oct; 5(10):577-87. PubMed ID: 18648354
    [TBL] [Abstract][Full Text] [Related]  

  • 17. BRCA-1 in sporadic epithelial ovarian cancer: lessons learned from the genetics of hereditary disease.
    Cannistra SA
    Clin Cancer Res; 2007 Dec; 13(24):7225-7. PubMed ID: 18094398
    [No Abstract]   [Full Text] [Related]  

  • 18. Image analysis and flow cytometric DNA studies of benign and malignant body cavity fluids: reappraisal of the role of current methods in the differential diagnosis of reactive versus malignant conditions.
    Lazcano O; Chen LM; Tsai C; Li CY; Katzmann JA; Sebo TJ; Kimlinger TK; Baker J
    Mod Pathol; 2000 Jul; 13(7):788-96. PubMed ID: 10912939
    [TBL] [Abstract][Full Text] [Related]  

  • 19. IGF axis gene expression patterns are prognostic of survival in epithelial ovarian cancer.
    Spentzos D; Cannistra SA; Grall F; Levine DA; Pillay K; Libermann TA; Mantzoros CS
    Endocr Relat Cancer; 2007 Sep; 14(3):781-90. PubMed ID: 17914107
    [TBL] [Abstract][Full Text] [Related]  

  • 20. A review and an update on the screening of epithelial ovarian cancer.
    Reynolds EA; Moller KA
    Curr Probl Cancer; 2006; 30(5):203-32. PubMed ID: 16996383
    [No Abstract]   [Full Text] [Related]  

    [Next]    [New Search]
    of 5.